Clinical Trials
14 trialsNCT05184088 2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3 Completed
NCT04304144 2025-03-05
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 2 Completed
NCT02245867 2025-02-07
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 1 Completed
NCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04659798 2024-07-08
DOrianT
Takeda
Completed
NCT05201911 2022-09-15
AT03-001
Attralus, Inc.
Phase 1 Completed
NCT01318902 2020-04-01
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Takeda
Phase 1 Completed
NCT02574676 2019-04-09
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Prothena Biosciences Ltd.
Completed
NCT02632786 2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2 Completed
NCT01707264 2018-08-28
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Prothena Biosciences Ltd.
Phase 1/2 Completed
NCT01777243 2018-07-24
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
GlaxoSmithKline
Phase 1 Completed
NCT01406314 2017-06-09
SAP Depleter Dose Assessment Study in Patients
GlaxoSmithKline
Phase 1 Completed
NCT02953808 2017-01-19
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
GlaxoSmithKline
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed